Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

Abstract

Summary:The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

Modulation of cyclophosphamide-induced early lung injury by allicin

“…CP is one of the most effective chemotherapeutic agents used in the treatment of cancers of breast (Levine et al, 2005;Hirano et al, 2008), lung (Sundstrom et al, 2005;Zhang et al, 2006), prostate (Nicolini et al, 2004), ovary (Donato et al, 2004), leukemia (Rao et al, 2005), lymphomas and non-Hodgkin's lymphoma. Significantly different from the CP-treated group using one-way ANOVA followed by the Tukey-Kramer multiple comparisons test (p50.05).…”

Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study

“…The 5-year survival rate for International Federation of Gynecology and Obstetrics (FIGO) Stage III disease is approximately 20-25% (1)(2)(3)(4)(5). Various sorts of consolidation therapy have been studied in a series of clinical trials, but none has shown to improve survival in ovarian cancer (6)(7)(8).…”

High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

“…Stiff et al 19 have reported the largest single centre experience of high-dose consolidation chemotherapy for relapsed ovarian cancer. This study shows that the best 20 and by Donato et al: 21 the survival of patients treated with highdose chemotherapy in CR was significantly better than that observed in other groups of patients. Another recently published randomised trial showed a trend for a better outcome for patients in CR treated with i.p.…”